Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Multicenter Study to Evaluate Efficacy and Safety of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Elective Surgical Procedures in Subjects With Severe Von Willebrand Disease

NCT02283268 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02283268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Multicenter Study to Evaluate Efficacy and Safety of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Elective Surgical Procedures in Subjects With Severe Von Willebrand Disease
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2015
Completion date
July 6, 2016
Enrollment
24 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease